and metastatic liver tumors. Percutaneous RFA for hepatic neoplasm is a recent innovation, but the results of preliminary clinical series and animal studies are encouraging and show that it is technically feasible and has minimal morbidity [4] [5] [6] [7] [8] .
MATERIALS AND METHODS

Patients
From January 2002 to October 2004, 10 patients underwent percutaneous US-guided RFA to treat intrahepatic cholangiocarcinoma. The study was approved by our institutional review board, and informed consent was obtained from all patients before the procedure. Of the 10 patients, two patients refused surgery and the other eight were not considered surgical candidates because of advanced age and either comorbid conditions (4 patients) or poor hepatic reserve (4 patients). No tumors were located near the intrahepatic great vessels.
There were six men and four women with a mean age of 66.2 years (range, 38-86 years) (Table) . All 10 patients had pathologic confirmation of the diagnosis from US-guided biopsy performed, either in advance or at the time of RFA. Tumor size ranged from 1.9 to 6.8 cm (mean, 3.4 cm). Tumors were classified into three groups depending on size: five tumors had a diameter of 3 cm or less, three tumors were between 3.1 and 5 cm, and two tumors were larger than 5 cm.
Radiofrequency tumor ablation technique
All patients were interviewed before treatment by one of the two experienced interventional radiologists (Yi-You Chiou, YYC; and Yi-Hong Chou, YHC), and were assessed with US before the procedure to determine whether the tumor was amenable to ablation under US guidance. Nine patients received meperidine analgesia and one patient was under conscious sedation (with droperidol, midazolam and fentanyl), administered and monitored by anesthesiologists.
Two different RFA devices were used with techniques that have been described previously [9, 10] : the RITA (radiofrequency interstitial tissue ablation) device (Rita Medical Systems, Mountain View, CA, USA) and the Radionics device (Radionics, Burlington, MA, USA). With the RITA device, ablation was performed using an expandable needle electrode (Starburst, 2-3 cm, or Starburst XL, 3-5 cm). With the Radionics device, treatment involved either a cluster (three-prong, 2.5 cm active tip) or a single (2 or 3 cm active tip) needle electrode, depending on the size of the tumor. Each tumor received one to four ablations in one session. The number of ablations performed in one session was based on the size of the tumor.
Imaging assessment
After RFA, all patients underwent immediate follow-up US or contrast-enhanced dynamic computed tomography (CT) to evaluate the possibility of bleeding or fluid accumulation. The efficacy of RFA was evaluated using contrast-enhanced dynamic CT 1 month after treatment and then every 3 months. Treated tumors were assessed for residual tumor and size changes. All follow-up images were also assessed for the development of new metastatic disease and ancillary peritumoral changes.
Residual disease was defined as persistent tumor without necrosis in an area or areas after ablation, as determined at the 1-month follow-up study. Recurrent disease was defined as new tumor development after at least one imaging study had demonstrated complete eradication of tumor. Assessment of images was performed in consensus by three experienced radiologists (YYC, YHC, and Jen-Huey Chiang). 
RESULTS
There were 12 sessions of RFA for 10 solid hepatic tumors in 10 patients. Eight patients were treated at a single session and the other two had two treatment sessions. Six tumors were located in the left hepatic lobe and four in the right hepatic lobe. Four patients were treated with the RITA device and six with the Radionics device. Of the patients treated with the RITA system, one was treated with the 2-3 cm active electrode and three were treated with the 3-5 cm active electrode. Of the patients treated with the Radionics system, one was treated with the 2 cm active tip electrode, four with the 3 cm active tip electrode, and one with the 2.5 cm cluster electrode. The duration of follow-up ranged from 4 to 38 months (mean, 20 months). Post-treatment CT showed total necrosis in eight of 10 tumors (80%) after one or two sessions of RFA ( Figure) . Residual tumor was observed in two patients with larger tumors (4.6 and 6.8 cm in diameter). One of these two patients died 14 months after percutaneous RFA. Complete necrosis was seen in all five tumors (100%) with diameters of 3.0 cm or less, two of three tumors (75%) with diameters of 3.1-5.0 cm, and one of two tumors (50%) larger than 5.0 cm. One recurrent tumor was found 16 months later in one patient with complete necrosis.
All patients tolerated the procedure with no major complications. One patient had a large biloma after the procedure, which resolved after 6 months with percutaneous drainage. Two patients had low-grade fever (< 38.5°C), which resolved in 1 week without antibiotic treatment. Two patients had pain or paresthesia around the puncture site for several days after the procedure, which resolved spontaneously in 2 and 4 weeks, respectively. All patients received a prescription for pain medication (acetaminophen or a non-steroidal anti-inflammatory drug) for 3-5 days on discharge from hospital. No patient experienced the postablative pain syndrome (pain, fever, malaise, and leukocytosis) described after hepatic RFA, and no patient received antibiotics before, during, or after the procedure.
DISCUSSION
Percutaneous RFA has been successfully used to treat liver neoplasms [4] [5] [6] [7] [8] 11, 12] . Radiofrequency thermal ablation works by converting radiofrequency waves into heat through ionic vibration. Alternating current passing from an electrode into the surrounding tissue causes ions to vibrate in an attempt to follow the change in the direction of 
cm recurrent cholangiocarcinoma (arrow) is evident in S4 of the left hepatic lobe. (C) CT 10 months after percutaneous ultrasound-guided radiofrequency ablation shows no enhancement of the nodule (arrow).
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the rapidly alternating current. It is the ionic friction that generates heat within the tissue and not the electrode itself. The higher the current, the more vigorous the motion of the ions and the higher the temperature reached over a period of time, eventually leading to coagulation necrosis and cell death. The purpose of RFA is to achieve local temperatures that are lethal to the targeted tissue. Generally, thermal damage to cells begins at 42°C; above 60°C, intracellular proteins are denatured, the lipid layer melts, and irreversible cell death occurs [13, 14] .
Although cholangiocarcinoma is generally considered to be slow growing, surgical resection offers the best opportunity for improving long-term survival. Chemotherapy and radiation have produced mixed results and are considered adjunct treatments to surgical resection [15, 16] . Intraluminal brachytherapy has been used within transhepatic biliary stents for cholangiocarcinoma, but posttreatment survival has generally been poor [15, 17, 18] .
The traditional treatment for localized intrahepatic cholangiocarcinoma is surgical resection [18] , but this method is not ideal for all tumors because some patients are unable or unwilling to undergo surgery or have limited functioning hepatic tissue [19] . Attention has recently focused on RFA as a minimally invasive treatment option for hepatic neoplasms, and various outcomes have been reported [14] [15] [16] [17] [18] 20] . The length of hospital stay, treatment cost, and risk of complications tend to be less with RFA than surgery.
The success rate of RFA in treating primary and metastatic hepatic tumors is largely dependent on tumor size [15, 17, 18] . In our study, no tumors smaller than 3 cm had residual or recurrent tumor on follow-up CT scans. Residual tumor was found in the two patients with tumors greater than 5 cm after a single session of RFA, and was still detected in one patient after a second session of RFA. This suggests that larger tumors are more difficult to completely eradicate with RFA. Other factors that may affect the success rate of RFA are tumor location and surrounding tissue. Centrally located tumors are more difficult to treat successfully as a result of heat loss caused by the extensive vascularity in the hepatic hilum. During RFA, heat loss occurs at the needle tip mainly through convection by means of blood circulation [13, 14] . On the other hand, surrounding fibrosis, as seen in cirrhotic patients [20] , is expected to reduce thermal conduction and heat dissipation, thus improving the treatment effect.
A major advantage of RFA is the ability to avoid tract bleeding and tumor seeding by coagulating the puncture tract during electrode withdrawal. No hematoma or tumor seeding after RFA was found in our study. The rate of serious complications after RFA is low. Some studies show that RFA of primary or metastatic hepatic tumors has a low complication rate, around 4.6-13.1% [21] [22] [23] . One of our 10 patients (10%) had a serious complication: a large biloma developed after RFA, but it was totally resolved after 6 months with percutaneous drainage. Two patients had local pain or paresthesia around the puncture site for several days or weeks, which subsided spontaneously. This, presumably, was due to transient damage to the intercostal or lumbar nerves in the affected dermatome. Two patients had transient low-grade fever after RFA, which resolved with oral analgesics. Other reported complications are abscess, pneumothorax, peritoneal hemorrhage, and acute cholecystitis, all of which can be treated conservatively [21, 22] .
One limitation of our study is that the outcome of RFA was judged by contrast enhancement on follow-up CT scan, with a lack of enhancement implying that no viable tumor remained. Lack of enhancement on follow-up imaging has generally been assumed to mean lack of viable tumor [19] . If the tumors were hypovascular on CT studies before RFA, we measured the density of the whole necrotic area after RFA to determine if there remained persistent viable tumor. From our experience, it is crucial to choose an ablation protocol and RFA electrode that can create a necrosis zone large enough to achieve a sufficient safety margin. We believe that lack of contrast enhancement on CT indicates complete tumor eradication, but follow-up surveillance imaging is warranted because long-term results of RFA for cholangiocarcinoma are lacking, and later scans should be used to detect local or metastatic lesions.
In conclusion, percutaneous US-guided RFA is a technique of rapidly increasing usefulness. It allows safe and effective treatment of hepatic tumors. As a minimally invasive procedure, it is ideally suited for patients who are not good surgical candidates. The success of RFA for intrahepatic cholangiocarcinoma was primarily influenced by the size of the tumor. RFA is a very promising technique that is most successful in treating intrahepatic cholangiocarcinoma smaller than 3 cm, and satisfactory in treating tumors between 3 and 5 cm. Long-term follow-up data regarding local and systemic recurrence and survival are still needed, and will provide additional guidelines for the most appropriate selection of patients suitable for this treatment. 
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